MK-677 (Ibutamoren)
- Status
- Phase 2, , not approved for human use
- Evidence
Small human trials, graded on 2 research benches
MK-677 (also called Ibutamoren or Nutrobal) is an orally-active, non-peptide ghrelin receptor (GHS-R1a) agonist developed by Merck Research Laboratories in the 1990s.
Reviewed
01Overview
What MK-677 (Ibutamoren) is
Unlike Ipamorelin, GHRP-2, or hexarelin, which are peptides usually given by injection, MK-677 is a small-molecule drug with high oral bioavailability. It is not the only oral growth hormone secretagogue tested in people: macimorelin (Macrilen), an oral ghrelin-receptor agonist, was FDA-approved on 20 December 2017 as a diagnostic test for adult growth hormone deficiency.
Read the full overviewShow less
MK-677 activates the same GHS-R1a receptor as endogenous ghrelin and produces a strong, sustained GH and IGF-1 elevation with a single daily oral dose. In the key 2-year trial in older adults, MK-677 25 mg/day raised serum IGF-1 about 1.5-fold and increased fat-free mass by 1.1 kg at 12 months, against a 0.5 kg loss on placebo (Nass et al., 2008).
The defining pharmacokinetic feature is the ~24-hour plasma half-life, which enables once-daily dosing and produces a sustained elevation of GH pulse amplitude throughout the day rather than the discrete 2-3 hour pulse of injectable GHS peptides. This is mechanistically distinct from the pulsatile GH architecture preserved by Ipamorelin, Tesamorelin, and MOD-GRF 1-29 — and is the source of both MK-677's popularity (convenience, durable IGF-1 elevation) and its characteristic side-effect profile (greater water retention, appetite stimulation, and insulin resistance than the injectable GHS peptides).
Before 2026 no MK-677 trial went beyond Phase 2; the hip fracture study was Phase 2b. The first Phase 3 trial, of ibutamoren as LUM-201 in children with growth hormone deficiency (NCT06948214, Lumos Pharma), started on 20 May 2026 and is recruiting. No Phase 3 trial has been run in sarcopenia or hip fracture. Despite positive efficacy signals, Merck discontinued development in the early 2010s, and the compound is not FDA-approved for any indication. It remains widely available as a research-use oral supplement and is one of the most popular compounds in the biohacking and bodybuilding communities specifically because of its oral route, 24-hour half-life, and significant effects on body composition, sleep, and appetite.
Typical dosing: 10-25 mg orally, once daily (typically pre-bed). Doses above 25 mg provide minimal additional benefit and increase side effects proportionally.
Regulatory status: Not FDA-approved. Sold as a research chemical in the US; WADA-banned for competitive athletes. Commonly used off-label in integrative medicine and is heavily represented in biohacking protocols. See our MK-677 Dosage Guide for protocol specifics and our Ipamorelin vs MK-677 comparison for stack-selection context.
How it works
MK-677 is a small-molecule full agonist at the growth hormone secretagogue receptor 1a (GHS-R1a) - the same receptor activated by endogenous ghrelin and the peptide GHS compounds (Ipamorelin, GHRP-2, GHRP-6, hexarelin). What distinguishes MK-677 is its pharmacokinetics and chemistry, not its primary receptor biology.
Read the full mechanismShow less
1. GHS-R1a agonism (Gq/11 / PLC / IP3 / Ca2+ pathway)
- GHS-R1a is a Class A GPCR expressed on pituitary somatotrophs (primary target for GH release) and at lower density on hypothalamic arcuate nucleus, gastric cells, pancreatic islets, and cardiomyocytes
- Ligand binding activates Gq/11, triggering phospholipase-C, which cleaves PIP into IP and DAG
- IP mobilizes intracellular Ca; DAG activates PKC
- Net effect: depolarization of the somatotroph and rapid exocytosis of preformed GH granules
MK-677 releases GH from cultured pituitary cells with an EC of ~1.3 nM - comparable to native ghrelin and the peptide GHS agonists (Patchett et al., 1995).
2. The critical difference: 24-hour half-life and sustained receptor engagement
This is where MK-677 diverges from all other GHS peptides:
| Compound | Half-life | Dosing | GH Profile |
|---|---|---|---|
| Ipamorelin | ~2 hours | 1-3x daily SC | Discrete pulses |
| GHRP-2 / GHRP-6 | ~20-30 min | 2-3x daily SC | Discrete pulses |
| MOD-GRF 1-29 | ~30 min | 1-3x daily SC | Discrete pulses (GHRH pathway) |
| Tesamorelin | ~30-50 min | 1x daily SC | Daily pulse |
| MK-677 | ~24 hours | 1x daily oral | Sustained amplification |
MK-677's 24-hour half-life produces sustained amplification of all GH pulses throughout the day rather than one or two discrete superimposed pulses. This is a double-edged property:
- Positive: Consistent IGF-1 elevation, once-daily oral convenience, stronger cumulative body composition effects
- Negative: Greater water retention, more appetite stimulation, more insulin resistance, and theoretical concerns about somatotroph desensitization with prolonged use
3. Pulsatility - preserved but dampened
Despite sustained receptor engagement, MK-677 does not fully abolish the pulsatile GH architecture. Somatostatin-mediated negative feedback can still modulate GH between pulses, and 24-hour GH profiling shows MK-677 increases both pulse amplitude and mean GH concentration without fully flattening the rhythm ([Copinschi et al., 1997]). This is a more favorable profile than CJC-1295-DAC's continuous GH elevation but less physiologic than ipamorelin's discrete pulses.
4. Downstream IGF-1 elevation
MK-677 produces the strongest sustained IGF-1 elevation of any oral or injectable GHS in non-GH-deficient adults:
- Week 2-4: IGF-1 rises ~50% from baseline
- Steady state at 4-8 weeks: IGF-1 ~80-100% elevated
- In the Nass 2008 2-year trial, mean IGF-1 rose from 180 to 283 ng/mL on MK-677 25 mg/day
5. Ghrelin-receptor effects beyond GH release
Because GHS-R1a is expressed widely, MK-677's sustained 24-hour agonism produces more prominent non-GH effects than the peptide GHS compounds:
- Appetite stimulation - the most noticeable secondary effect; direct action on hypothalamic NPY/AgRP neurons; appetite rose in 29 of 43 people on MK-677 against 8 of 22 on placebo in the 2-year trial, which did not measure caloric intake (Nass et al., 2008)
- Gastric emptying - accelerated; may cause mild GI discomfort in some users
- Insulin resistance - multi-mechanism: GH-mediated hepatic glucose output increase, ghrelin-mediated glucose intolerance, fluid-shift-related changes; meaningfully worse on MK-677 than ipamorelin at equivalent GH exposure
- Slow-wave sleep enhancement - consistent with GHS pharmacology; often reported as the most immediately noticeable benefit
- Cortisol and prolactin - MK-677 is generally selective like ipamorelin, producing minimal elevations at clinical doses (much less than GHRP-2/6); however at high doses (>50 mg/day) some cortisol elevation has been reported
Studied for
- Growth hormone deficiency
- Muscle wasting
- Osteoporosis
- Aging
- Alzheimer's disease
Benefits listed
- Increased IGF-1 (~80-100% over baseline at steady state)
- Improved slow-wave sleep architecture
- Lean body mass increase (demonstrated in 2-year older adult trial)
- Improved connective tissue / wound / bone repair
Show 4 moreShow less
- Once-daily oral convenience (no injections)
- Appetite stimulation (benefit for underweight or hard-gainer populations)
- Enhanced recovery between training sessions
- Potential bone mineral density improvement
02Research
Free with emailWhat the research shows
Graded on 2 research benches
Reference pages that put MK-677 (Ibutamoren) next to the compounds people pair it with: roles, evidence, overlap and conflicts. No dosing. Research use only.
Unlock the research summary
Enter your email to keep reading. It is free, and it opens these sections on every compound page in this browser.
- A summary of the key research
- Safety and side effects
- A link to the PubMed results
You also get the free peptide cheat sheet by email. Unsubscribe anytime.
Have an account? Sign in
03Safety
MK-677 side effects and interactions
Side effects
Moderate riskStop use if
- Active cancer
- Uncontrolled diabetes or insulin resistance
- Active edema
Common
- Increased appetite
- Water retention
- Lethargy
- Elevated fasting glucose
- Increased cortisol
Less common
- Insulin resistance
- Carpal tunnel syndrome
- Joint pain
- Prolactin elevation
Who should not use it
Contraindications
Absolute contraindications
- History of congestive heart failure (CHF) or any NYHA class II-IV cardiac dysfunction - the Adunsky 2011 hip-fracture Phase IIb trial (25 mg/day, N=123) was terminated early after a CHF safety signal in frail elderly patients; MK-677's water retention and sustained GH elevation can precipitate decompensation in vulnerable hearts
- Active malignancy - GH/IGF-1 axis may accelerate tumor growth. No direct MK-677 cancer data but inferred from general GH/IGF-1 literature ([Renehan et al., 2004])
- Active diabetic retinopathy (proliferative or severe non-proliferative) - GH elevation can worsen retinopathy
- History of acromegaly or pituitary adenoma - superimposing sustained exogenous GH amplification on an already-hyperactive axis risks accelerating tumor growth and acromegalic progression
- Pregnancy or breastfeeding - no safety data; do not use
- Age <18 - pediatric GHD is managed with sermorelin or recombinant GH under endocrinology supervision, not MK-677
Read all the contraindications and cautionsShow less
Relative contraindications (consult physician before use)
- Type 2 diabetes or pre-diabetes - MK-677 produces measurable glucose intolerance; use requires close monitoring and usually metformin co-therapy
- Uncontrolled hypertension - fluid retention can exacerbate blood pressure
- History of carpal tunnel syndrome - fluid retention and connective tissue expansion can worsen symptoms
- Hypothyroidism - optimize thyroid first
- Chronic kidney disease (CKD stage III+) - fluid retention can contribute to edema; dose reduction and close monitoring
- History of pituitary or hypothalamic surgery or radiation - altered somatotroph response; unpredictable
Drug interactions
- Insulin and oral hypoglycemics - MK-677 impairs glucose tolerance; antidiabetic medication may need adjustment
- Corticosteroids (chronic systemic) - suppress GH axis and blunt MK-677 response
- CYP3A4 inhibitors/inducers - MK-677 is CYP3A4 metabolized; major inhibitors (ketoconazole, ritonavir) can elevate plasma levels; inducers (rifampin, carbamazepine) can reduce efficacy
- Exogenous GH (Somatropin) - do not combine
- Other GHS peptides or CJC-1295-DAC - do not combine (redundant, additive side effects)
Specific drug combinations that require caution
- SSRI + MK-677 - no direct interaction but both can cause fluid retention; monitor
- NSAID chronic + MK-677 - both retain fluid; monitor edema
- Statins + MK-677 - no specific interaction; standard monitoring
Monitoring requirements
- Baseline: IGF-1, fasting glucose, HbA1c, insulin, complete metabolic panel, thyroid panel, CBC, lipid panel, PSA (men >40), echocardiogram if any cardiac history
- Week 4-6: IGF-1, fasting glucose, insulin
- Week 8-12: Full panel + blood pressure + weight trend
- Every 12 weeks on long-term therapy: Full panel
- Annually: Full panel + consider imaging if symptomatic
Discontinuation criteria
Stop MK-677 and consult a clinician if you develop:
- Any chest pain, dyspnea, peripheral edema with weight gain >3 kg, orthopnea - possible CHF; urgent
- New or worsening carpal tunnel symptoms
- IGF-1 > 350 ng/mL (supraphysiologic in most adults)
- Fasting glucose consistently >115 mg/dL or HbA1c rising >0.4 points despite metformin
- Any new palpable mass, changing mole, unexplained weight loss (cancer workup)
- Severe headache, visual changes (rule out pituitary pathology)
- Unexplained fatigue, edema, or rapid weight gain (assess fluid balance, thyroid, glucose)
Interactions
6 pairings in our record: 2 to avoid, 3 with a caution and 1 noted as compatible or synergistic. Compatible and synergistic are notes from the record, not safety findings.
Ipamorelin
AvoidBoth are GHS-R1a (ghrelin-receptor) agonists - combining them is redundant and stacks side effects (water retention, appetite, insulin resistance) without added GH benefit; not recommended
Insulin
AvoidMK-677 significantly impairs insulin sensitivity - dangerous combination for diabetics
Semaglutide
CautionMK-677 increases appetite and insulin resistance - directly opposes semaglutide effects
IGF-1 LR3
CautionMK-677 already elevates IGF-1 - adding exogenous IGF-1 risks excessive growth factor levels
Tesamorelin
CautionBoth elevate GH - stacking may cause excessive GH/IGF-1 levels
CJC-1295
SynergisticCombines GH secretagogue with GHRH analog for amplified GH pulses
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
Need bloodwork before starting?
Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount.
04Dosing
Free with emailMK-677 dosage and protocols
- Dose range
- 10,000–25,000 mcg (10–25 mg) oral daily
- Dosing
- Once daily, typically at bedtime
- Common vials
- 25mg capsules, 30mL liquid
Unlock the dosing protocols
Enter your email to keep reading. It is free, and it opens these sections on every compound page in this browser.
- Dose, route, how often and how long
- A titration schedule
- Beginner, intermediate and advanced protocols
- Reconstitution and handling notes
You also get the free peptide cheat sheet by email. Unsubscribe anytime.
Have an account? Sign in
05Prices
MK-677 (Ibutamoren) prices
2 listings from 2 vendors, opening in the Featured order.
- Pack prices
- $74.99 to $89.99
- Lowest per mg
- Not listed
- Vendors
- 2
- Listings
- 2 (capsule)
Prices as the vendors list them, last recorded 8 October 2026.
| Vendor | Product | Price | Buy |
|---|---|---|---|
MK-677 (Ibutamoren) Capsules 10 mg capsule, capsules (10 mg) In stock | $89.99 No mg count | Buy MK-677 (Ibutamoren) Capsules 10 mg at Disguised Alpha | |
MK-677 Capsules 60ct capsule, 60 capsules In stock | $74.99 No mg count | Buy MK-677 Capsules 60ct at Half Nattys |
Vendors selling MK-677 (Ibutamoren)(2: trust score, certificates, payment, shipping)
- Half Nattys1 listing, from $74.99
Trust Score 50/100, 0 of 31 certificate records read, pays by card, crypto, Zelle, ships to the US
- Disguised Alpha1 listing, from $89.99
Trust Score 50/100, 0 of 36 certificate records read, pays by card, crypto, bank transfer, ships to the US, the EU, the UK
Every supplier above is graded 0 to 100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank. How we score these vendors
Price history(2 days with a recorded price)
06Chemistry
Chemistry and structure
- Molecular formula
- C27H36N4O5S
- Molecular mass
- 528.67 g/mol
- CAS number
- 159634-47-6
- IUPAC name
- 2-amino-2-methyl-N-[1-(methylsulfonylmethyl)-2-(1-methylpropyl)-3-(1H-indol-3-ylmethyl)...] (complex structure)
08Questions
Frequently asked questions
Is MK-677 a SARM or a steroid?
Neither. MK-677 (Ibutamoren) is a growth hormone secretagogue - a small-molecule agonist at the ghrelin receptor (GHS-R1a) that stimulates the pituitary to release more growth hormone. It has no direct androgen receptor activity (unlike SARMs) and is not a steroid. The receptor it activates is the same one activated by the natural hunger hormone ghrelin. MK-677 increases your body's own GH and IGF-1 production via the pituitary; it does not introduce exogenous hormones. This mechanistic distinction matters for side-effect profile and regulatory classification.
How much IGF-1 will MK-677 raise my levels by?
At the standard 25 mg/day dose, IGF-1 typically rises 80-100% above baseline and reaches steady state within 4-8 weeks. In the pivotal Nass 2008 2-year trial in older adults, mean IGF-1 rose from 180 to 283 ng/mL (57% in that older population; younger healthy adults typically see larger percentage increases). At the lower 10 mg/day dose, expect ~40-50% IGF-1 elevation. Above 25 mg/day the dose-response plateaus - higher doses do not produce proportional IGF-1 elevation but do produce proportional side effects.
Why does MK-677 cause so much water retention and hunger compared to ipamorelin?
The 24-hour half-life of MK-677. Ipamorelin clears in ~2 hours, producing a discrete 2-3 hour GH pulse and transient appetite effect. MK-677 remains active at the ghrelin receptor around the clock, producing sustained GH elevation AND continuous ghrelin-receptor tone. The continuous ghrelin signal drives the hunger effect directly (ghrelin is the hunger hormone), and the sustained GH elevation drives fluid shifts and water retention. This is also why MK-677 causes more insulin resistance than injectable GHS peptides at equivalent total GH exposure - sustained vs pulsatile receptor engagement produces different downstream metabolic effects.
Does MK-677 shut down natural GH production?
The evidence is nuanced. In the Nass 2008 2-year trial, GH and IGF-1 remained elevated throughout the study - no evidence of tachyphylaxis. Some users report reduced subjective response after 3-4 months of continuous use, but this has not been consistently demonstrated in controlled trials. Because MK-677 preserves some pulsatility (unlike CJC-1295 with DAC), somatostatin-mediated negative feedback can still operate between pulses - which reduces (but does not eliminate) long-term desensitization risk. The conservative approach is cycling 8-16 weeks on / 4-6 weeks off; the Nass-trial-reference approach is continuous dosing with quarterly bloodwork.
What's the difference between MK-677 and injectable growth hormone secretagogues like ipamorelin?
Four key differences: (1) Route - MK-677 is oral, ipamorelin is subcutaneous injection; (2) Pharmacokinetics - MK-677 has a 24-hour half-life producing sustained amplification, ipamorelin has a 2-hour half-life producing discrete pulses; (3) Side effects - MK-677 produces more water retention, appetite stimulation, and glucose intolerance due to sustained receptor engagement; ipamorelin is cleaner but less convenient; (4) Stacking - ipamorelin pairs with GHRH analogs for 3-5x pulse amplification; MK-677 is used standalone because its sustained signal already amplifies endogenous GHRH pulses. Both target the same receptor (GHS-R1a).
Should I take MK-677 with food or on an empty stomach?
Empty stomach preferred. Fasted dosing produces approximately 15% higher Cmax than fed dosing. Pre-bed (2+ hours after last meal) is standard: (1) maximizes absorption, (2) aligns with the nocturnal GH burst, (3) enhances slow-wave sleep. If empty stomach is not practical, MK-677 can be taken with food - the efficacy penalty is small (~15%). Avoid high-fat meals immediately before dosing as they more meaningfully slow absorption. Alcohol does not significantly interact pharmacologically but impairs sleep quality - avoid within 4 hours of dosing for full sleep-architecture benefit.
Is MK-677 safe for long-term use?
The best data we have is the Nass 2008 trial (2 years in older adults, 25 mg/day), which showed sustained IGF-1 elevation and lean mass gain with a modest HbA1c rise (0.2 percentage points at 12 months) and was generally well tolerated, with no congestive heart failure reported. The CHF safety signal that drives the cardiac contraindication instead comes from the separate Adunsky 2011 hip-fracture trial in frail elderly patients, which was stopped early for that reason. Beyond 2 years, safety is extrapolated from general GH/IGF-1 literature. The safety considerations are: (1) glucose intolerance is real and dose-dependent - manage with diet, monitoring, and metformin if needed; (2) fluid retention should be monitored, especially in users with any cardiac history (absolute contraindication if CHF); (3) IGF-1 elevation should stay within age-adjusted reference range - periodic monitoring is required. For most healthy users, 12-16 weeks on / 4-6 weeks off with full bloodwork is the conservative approach; continuous use is defensible with monitoring but not fully characterized beyond 2 years.
Can I stack MK-677 with semaglutide or TRT?
Yes to both. MK-677 + semaglutide or tirzepatide is a body recomposition stack: GLP-1 drives caloric deficit and fat loss, MK-677 preserves lean body mass via GH/IGF-1 elevation. The appetite dimensions run in opposite directions - GLP-1 suppresses, MK-677 stimulates - net is usually still hypocaloric but less aggressively so. For more moderate appetite balance, use MK-677 at 10 mg instead of 25 mg. MK-677 + TRT is complementary: HPG and GH axes are independent and combined optimization is standard in integrative hormone clinics. Add metformin 500-1000 mg/day if glucose management is a concern. DO NOT stack MK-677 with ipamorelin, GHRP-2/6, or hexarelin - all are GHS-R1a agonists, making the combination redundant.
Is MK-677 legal and is it banned in sports?
MK-677 is not FDA-approved for any indication. It is sold as a research chemical in the United States - legal to possess, research, and sell with appropriate labeling; enforcement on personal use varies. Some integrative medicine clinics prescribe it off-label through compounding pharmacies. WADA (World Anti-Doping Agency) has banned MK-677 in competitive athletics since 2012 - it is on the S2 prohibited list (peptide hormones, growth factors, related substances). If you are a competitive athlete subject to testing, MK-677 will produce a positive result for up to 6 weeks after discontinuation. See our Best Peptide Vendors 2026 guide for sources; always verify HPLC purity and COA before use.
How long does it take to see results from MK-677?
Timeline from Phase II data: (1) Sleep quality improvement - most users report deeper sleep within 3-7 nights; this is the most immediate noticeable effect; (2) Appetite increase - immediate (days 1-3); (3) Water retention / scale weight increase - 1-3 kg in the first 2 weeks; stabilizes by week 4; (4) IGF-1 rise - detectable at week 2, reaches steady state at 4-8 weeks; (5) Lean body mass gain - measurable at 8-12 weeks, continues to accrue over months (Nass 2008 showed 1.1 kg gain at 24 months); (6) Subjective recovery improvement - most users report this at weeks 2-4; (7) Body composition change - fat loss is modest unless caloric deficit maintained; lean mass gain is the primary visible effect. Discontinuation reverses effects over 2-4 weeks.
How many vendors sell MK-677 (Ibutamoren), and what does it cost per mg?
2 of the vendors BodyHackGuide tracks list MK-677 (Ibutamoren) (2 listings). The lowest listed price BodyHackGuide has recorded for MK-677 (Ibutamoren) is $74.99. No MK-677 (Ibutamoren) listing recorded as in stock carries a milligram count, so BodyHackGuide states no price per milligram for MK-677 (Ibutamoren).
Which vendors have third-party COAs for MK-677 (Ibutamoren) on file at BodyHackGuide?
BodyHackGuide holds 12 third-party certificate records for MK-677 (Ibutamoren), from Disguised Alpha and Half Nattys. No editor has read any of BodyHackGuide's 12 certificate records for MK-677 (Ibutamoren). The laboratory named on BodyHackGuide's MK-677 (Ibutamoren) certificate records is Freedom Diagnostics Testing, and the newest test date on them is 18 September 2026. Each vendor page on BodyHackGuide shows how many certificate records BodyHackGuide holds for that vendor and links to each record that has its own page.
Free 2026 Peptide Cheat Sheet (PDF)
38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers.

